Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Saved in:
| Title: | Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. |
|---|---|
| Authors: | Balmaña J; Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain., Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany., Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Delaloge S; Breast Cancer Unit, Department of Cancer Medicine, Gustave Roussy, Villejuif, France., Labidi-Galy I; Department of Oncology, Geneva University Hospital, Department of Medicine, Division of Oncology, Faculty of Medicine, University of Geneva, Geneva, Switzerland., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Eisen AF; Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., You B; Department of Medical Oncology, Hospices Civils of Lyon Cancer Institute, Centre for Therapeutic Investigation in Oncology and Haematology of Lyon, Lyon Sud Hospital Centre, Lyon, France.; Faculty of Medicine of Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.; GINECO-GINEGEPS, Paris, France., Bourgeois H; Medical Oncology Department, Victor Hugo Clinic-Jean Bernard Center, Le Mans, France., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.; Cancer Research Center of Marseille, Aix-Marseille University, French National Centre for Scientific Research, National Institute for Health and Medical Research, Marseille, France., Kemp Z; Breast Cancer Unit, The Royal Marsden NHS Foundation Trust, London, UK., Swampillai A; Department of Clinical Oncology, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, UK., Jankowski T; Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland., Sohn JH; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Poddubskaya E; Surgical Department N2, Clinical Center VitaMed, Moscow, Russia., Mukhametshina G; Ministry of Health of the Republic of Tatarstan, Kazan, Russia., Aksoy S; Medical Oncology Department, Hacettepe University Cancer Institute, Ankara, Turkey., Timcheva CV; Medical Oncology Department, MHAT Nadezhda, Sofia, Bulgaria., Park-Simon TW; Frauenklinik, Hannover Medical School, Hannover, Germany., Antón-Torres A; Department of Medical Oncology, Miguel Servet University Hospital and Aragon Health Research Institute, Zaragoza, Spain., John E; Statistics, AstraZeneca, Cambridge, UK., Baria K; US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA., Gibson I; Global Medical Affairs, AstraZeneca, Cambridge, UK., Gelmon KA; Department of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada. kgelmon@bccancer.bc.ca. |
| Corporate Authors: | LUCY investigators |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Apr; Vol. 204 (2), pp. 237-248. Date of Electronic Publication: 2023 Dec 19. |
| Publication Type: | Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38112922 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Balmaña+J%22">Balmaña J</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Fasching+PA%22">Fasching PA</searchLink>; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.<br /><searchLink fieldCode="AU" term="%22Couch+FJ%22">Couch FJ</searchLink>; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Delaloge+S%22">Delaloge S</searchLink>; Breast Cancer Unit, Department of Cancer Medicine, Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Labidi-Galy+I%22">Labidi-Galy I</searchLink>; Department of Oncology, Geneva University Hospital, Department of Medicine, Division of Oncology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.<br /><searchLink fieldCode="AU" term="%22O'Shaughnessy+J%22">O'Shaughnessy J</searchLink>; Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Park+YH%22">Park YH</searchLink>; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Eisen+AF%22">Eisen AF</searchLink>; Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22You+B%22">You B</searchLink>; Department of Medical Oncology, Hospices Civils of Lyon Cancer Institute, Centre for Therapeutic Investigation in Oncology and Haematology of Lyon, Lyon Sud Hospital Centre, Lyon, France.; Faculty of Medicine of Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.; GINECO-GINEGEPS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bourgeois+H%22">Bourgeois H</searchLink>; Medical Oncology Department, Victor Hugo Clinic-Jean Bernard Center, Le Mans, France.<br /><searchLink fieldCode="AU" term="%22Gonçalves+A%22">Gonçalves A</searchLink>; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.; Cancer Research Center of Marseille, Aix-Marseille University, French National Centre for Scientific Research, National Institute for Health and Medical Research, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Kemp+Z%22">Kemp Z</searchLink>; Breast Cancer Unit, The Royal Marsden NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Swampillai+A%22">Swampillai A</searchLink>; Department of Clinical Oncology, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Jankowski+T%22">Jankowski T</searchLink>; Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.<br /><searchLink fieldCode="AU" term="%22Sohn+JH%22">Sohn JH</searchLink>; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Poddubskaya+E%22">Poddubskaya E</searchLink>; Surgical Department N2, Clinical Center VitaMed, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Mukhametshina+G%22">Mukhametshina G</searchLink>; Ministry of Health of the Republic of Tatarstan, Kazan, Russia.<br /><searchLink fieldCode="AU" term="%22Aksoy+S%22">Aksoy S</searchLink>; Medical Oncology Department, Hacettepe University Cancer Institute, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Timcheva+CV%22">Timcheva CV</searchLink>; Medical Oncology Department, MHAT Nadezhda, Sofia, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Park-Simon+TW%22">Park-Simon TW</searchLink>; Frauenklinik, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Antón-Torres+A%22">Antón-Torres A</searchLink>; Department of Medical Oncology, Miguel Servet University Hospital and Aragon Health Research Institute, Zaragoza, Spain.<br /><searchLink fieldCode="AU" term="%22John+E%22">John E</searchLink>; Statistics, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Baria+K%22">Baria K</searchLink>; US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Gibson+I%22">Gibson I</searchLink>; Global Medical Affairs, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Gelmon+KA%22">Gelmon KA</searchLink>; Department of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada. kgelmon@bccancer.bc.ca. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22LUCY+investigators%22">LUCY investigators</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2024 Apr; Vol. 204 (2), pp. 237-248. <i>Date of Electronic Publication: </i>2023 Dec 19. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38112922 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10549-023-07165-x Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 237 Titles: – TitleFull: Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Balmaña J – PersonEntity: Name: NameFull: Fasching PA – PersonEntity: Name: NameFull: Couch FJ – PersonEntity: Name: NameFull: Delaloge S – PersonEntity: Name: NameFull: Labidi-Galy I – PersonEntity: Name: NameFull: O'Shaughnessy J – PersonEntity: Name: NameFull: Park YH – PersonEntity: Name: NameFull: Eisen AF – PersonEntity: Name: NameFull: You B – PersonEntity: Name: NameFull: Bourgeois H – PersonEntity: Name: NameFull: Gonçalves A – PersonEntity: Name: NameFull: Kemp Z – PersonEntity: Name: NameFull: Swampillai A – PersonEntity: Name: NameFull: Jankowski T – PersonEntity: Name: NameFull: Sohn JH – PersonEntity: Name: NameFull: Poddubskaya E – PersonEntity: Name: NameFull: Mukhametshina G – PersonEntity: Name: NameFull: Aksoy S – PersonEntity: Name: NameFull: Timcheva CV – PersonEntity: Name: NameFull: Park-Simon TW – PersonEntity: Name: NameFull: Antón-Torres A – PersonEntity: Name: NameFull: John E – PersonEntity: Name: NameFull: Baria K – PersonEntity: Name: NameFull: Gibson I – PersonEntity: Name: NameFull: Gelmon KA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2024 Apr Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1573-7217 Numbering: – Type: volume Value: 204 – Type: issue Value: 2 Titles: – TitleFull: Breast cancer research and treatment Type: main |
| ResultId | 1 |
